Trulicity (Dulaglutide) in Adolescents Ages 12 to 17: Developmental Impact

Why Developmental Context Matters Before Prescribing Dulaglutide to Teens

Prescribing any chronic medication to a 12 to 17-year-old is not the same as prescribing it to an adult. The adolescent body is running multiple simultaneous developmental programs: the hypothalamic-pituitary-gonadal (HPG) axis is activating, cortical and trabecular bone is accruing at its lifetime peak rate, and the prefrontal cortex is still pruning synapses through roughly age 25. A drug that mildly perturbs appetite, nausea thresholds, or nutrient absorption can ripple into all three systems.

Type 2 diabetes in adolescents is itself a more aggressive disease than the adult-onset form. A 2021 analysis in Diabetes Care showed that youth-onset type 2 diabetes progresses to beta-cell failure faster and carries earlier cardiovascular complications than adult-onset disease [1]. Effective glucose control matters. The question is whether dulaglutide's benefits in adolescents outweigh any developmental risks over a treatment course that may span decades.

The Regulatory Pathway That Brought Dulaglutide to Teens

The FDA approved dulaglutide for pediatric patients aged 10 and older in June 2020, based on the AWARD-PEDS trial [2]. That approval required Eli Lilly to conduct dedicated pediatric studies under the Pediatric Research Equity Act (PREA), which mandates child-specific pharmacokinetic and safety data rather than simply extrapolating adult results [3].

The PREA obligation is clinically significant: it means the developmental safety database for dulaglutide in adolescents is based on actual pediatric subjects, not modeled assumptions.

AWARD-PEDS: What the Key Trial Actually Showed

AWARD-PEDS was a 26-week, double-blind, placebo-controlled trial enrolling 154 patients (ages 10 to 17) with type 2 diabetes [4]. The 12 to 17 subgroup represented the majority of enrollees. Participants were randomized to dulaglutide 0.75 mg weekly, dulaglutide 1.5 mg weekly, or placebo, all added to background metformin with or without basal insulin.

Glycemic Outcomes

Mean HbA1c fell by 0.6 percentage points with the 0.75 mg dose and by 0.9 percentage points with the 1.5 mg dose, versus a rise of 0.6 percentage points in the placebo group (P<0.001 for both comparisons) [4]. That difference of roughly 1.2 to 1.5 percentage points is clinically meaningful given the accelerated beta-cell decline typical of adolescent type 2 diabetes.

The proportion of patients achieving HbA1c <7.0% was 51% in the 1.5 mg group versus 14% in the placebo group.

Growth and Pubertal Staging

Height, weight, and Tanner staging were collected at baseline and at weeks 13 and 26. No statistically significant difference in height velocity or Tanner stage progression was detected between active treatment arms and placebo [4]. Body weight showed a modest net reduction of approximately 0.9 kg in the 1.5 mg group versus a 1.4 kg gain in placebo, a difference driven largely by blunted weight gain rather than active weight loss.

Safety Profile in Adolescents

Gastrointestinal adverse events were the most common reason for dose interruption. Nausea occurred in 17% of actively treated patients, vomiting in 10%, and diarrhea in 8% [4]. No cases of pancreatitis were reported during the 26-week period. Hypoglycemia rates were low and comparable to placebo when dulaglutide was used without concomitant sulfonylurea or insulin intensification.

Bone Health During Peak Accrual Years

Why Adolescence Is the Critical Window

Approximately 40 to 60% of peak bone mass is deposited during the pubertal growth spurt, a window that spans roughly ages 11 to 17 in girls and 13 to 19 in boys [5]. Interventions that reduce caloric intake, alter calcium and vitamin D absorption, or disrupt sex hormone secretion can permanently reduce peak bone mass, raising lifetime fracture risk.

What GLP-1 Receptor Agonists Do to Bone

GLP-1 receptors are expressed on osteoblasts. Preclinical data suggest GLP-1 agonism may modestly stimulate bone formation, but the clinical translation in adolescents is unknown [6]. In adult type 2 diabetes populations, GLP-1 receptor agonists as a class appear neutral to mildly protective on fracture risk compared with other antidiabetic agents, based on a 2021 meta-analysis of 22 randomized controlled trials (N=57,838) [7].

AWARD-PEDS did not include DXA scanning, so direct bone mineral density data in adolescents on dulaglutide simply does not exist in the published literature. That gap is not reassuring or alarming; it is a genuine unknown.

Clinical Monitoring Recommendation

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends DXA assessment in adolescents on chronic weight-affecting medications [8]. For dulaglutide specifically, the HealthRX medical team advises baseline DXA at treatment initiation in patients younger than 16, with repeat scanning at 12 months if caloric intake drops more than 15% from estimated maintenance.

Pubertal Development and HPG Axis Considerations

GLP-1 Receptors in Reproductive Tissue

GLP-1 receptors are expressed in the hypothalamus, pituitary, and gonadal tissue in both human and rodent models [9]. In adults, GLP-1 agonism does not reliably alter luteinizing hormone (LH) or follicle-stimulating hormone (FSH) secretion at therapeutic doses, but those data come from fully mature HPG axes.

The adolescent HPG axis is still establishing its pulsatile GnRH rhythm. Whether chronic GLP-1 receptor stimulation subtly modulates that rhythm has not been studied in a controlled trial.

What Tanner Data From AWARD-PEDS Can and Cannot Tell Us

Tanner staging is a visual assessment of secondary sex characteristic development. AWARD-PEDS showed no group-level difference in staging over 26 weeks [4]. That is reassuring but limited: 26 weeks is insufficient to detect subtle delays in pubertal tempo, and the trial was not powered to detect hormonal differences.

Clinicians should document Tanner stage at every 6-month visit and refer to pediatric endocrinology if a patient on dulaglutide shows no Tanner progression over 12 months without another obvious cause.

Menstrual Cycle Tracking in Female Adolescents

Weight loss or caloric restriction in adolescent females can suppress LH pulsatility and cause secondary amenorrhea. A 2018 study in the Journal of Clinical Endocrinology and Metabolism found that weight loss exceeding 10% of body weight in adolescent females was associated with menstrual irregularity in 28% of cases [10]. Because dulaglutide can suppress appetite and reduce caloric intake, female patients should be asked about menstrual regularity at every visit.

Neurodevelopmental Considerations

The developing adolescent brain expresses GLP-1 receptors in the prefrontal cortex, hippocampus, and reward circuitry. GLP-1 agonists reduce dopaminergic signaling in mesolimbic pathways in rodent models, which is one proposed mechanism for appetite suppression [11]. Whether this signaling reduction affects motivation, learning consolidation, or mood in the still-maturing adolescent brain is not established.

No neuropsychiatric signal emerged in AWARD-PEDS over 26 weeks. Depression and anxiety screening scores were not systematically reported in the published trial, which is a gap worth noting for real-world practice.

Clinicians at HealthRX routinely screen adolescent patients on dulaglutide with the PHQ-A (adolescent-specific Patient Health Questionnaire) at baseline and every 3 months. Any score of 10 or higher prompts mental health referral before continuing therapy.

Insulin Sensitivity, Adiposity, and Metabolic Maturation

Why Insulin Resistance Peaks in Puberty

Puberty normally produces a transient 30 to 50% reduction in insulin sensitivity mediated by growth hormone secretion, which typically resolves after Tanner stage 4 to 5 [12]. In adolescents with type 2 diabetes, that physiologic insulin resistance compounds underlying beta-cell dysfunction, creating a particularly hostile metabolic environment.

Dulaglutide addresses this partly through glucose-dependent insulin secretion augmentation and partly through body weight reduction. The blunted weight gain seen in AWARD-PEDS may improve insulin sensitivity independently of direct GLP-1 receptor effects on pancreatic beta cells.

Comparing Dulaglutide to Other Pediatric Options

The TODAY2 cohort study (N=500+, mean follow-up 10.2 years) showed that metformin monotherapy in adolescent type 2 diabetes fails to maintain glycemic control in a majority of patients within 3 to 5 years [13]. Adding dulaglutide to metformin in AWARD-PEDS produced durable HbA1c reductions at 26 weeks even in patients who had already failed metformin monotherapy.

Liraglutide (Victoza) received pediatric approval in 2019 (ages 10 and older) and showed a 0.64% HbA1c reduction versus placebo at 26 weeks in the ELLIPSE trial (N=134) [14]. The two agents have not been compared head-to-head in adolescents. Dulaglutide's once-weekly dosing versus liraglutide's once-daily injection is a practical advantage in adherence-challenged adolescent populations.

Exenatide extended-release is also once weekly and carries pediatric labeling, but its trial database in adolescents is smaller than either liraglutide or dulaglutide.

Nutrition, Caloric Intake, and Growth Velocity

Ensuring Adequate Macronutrient Intake

Adolescents require approximately 2,000 to 3,200 kcal/day depending on sex, Tanner stage, and activity level. Dulaglutide's appetite-suppressing effect, via delayed gastric emptying and hypothalamic GLP-1 receptor activation, may reduce intake below growth-adequate thresholds in a subset of patients.

A 2022 review in Nutrients noted that GLP-1 agonist-related nausea reduces dietary variety as well as total caloric intake, with protein intake often disproportionately affected when patients self-restrict to soft, easily tolerated foods [15].

Registered dietitian involvement at initiation is not optional. Adolescent patients on dulaglutide should receive a structured meal plan that targets age-appropriate protein intake (1.0 to 1.2 g/kg/day) and calcium (1,300 mg/day per NIH Office of Dietary Supplements guidelines).

Monitoring Height Velocity

Height should be measured using a wall-mounted stadiometer (not a door frame) at every 3-month visit. A decline in height velocity below the 10th percentile for age and sex on a CDC growth chart should prompt assessment of nutritional adequacy before attributing the change to disease progression.

Dosing, Administration, and Titration in Adolescents

The FDA-approved starting dose is 0.75 mg subcutaneously once weekly. If additional glycemic control is needed after at least 4 weeks, the dose may be increased to 1.5 mg once weekly [2]. No pediatric dose above 1.5 mg is approved.

The autoinjector pen is the same device used in adults. Adolescents aged 12 to 17 can generally self-administer after a single training session, which is supported by the FDA label's instructions-for-use validation data. Injection sites (abdomen, thigh, upper arm) should be rotated to minimize subcutaneous nodule formation.

If a dose is missed, it should be administered as soon as the patient remembers, provided at least 3 days remain before the next scheduled dose. If fewer than 3 days remain, the missed dose should be skipped.

When to Discontinue or Switch

Dulaglutide should be discontinued in adolescents who develop:

• Persistent nausea or vomiting causing more than 5% body weight loss below baseline over 8 weeks
• Any personal or family history of medullary thyroid carcinoma or MEN2 syndrome (black-box contraindication)
• Confirmed pancreatitis (acute or chronic)
• HbA1c above 10% despite maximum-approved dosing, indicating beta-cell failure requiring basal insulin

The ADA Standards of Medical Care in Diabetes 2024 state: "In youth with type 2 diabetes, pharmacologic therapy should be intensified when HbA1c targets are not met within 3 months of initiating or adjusting treatment" [16]. If dulaglutide at 1.5 mg fails the 3-month target, combination with basal insulin is the recommended next step rather than switching GLP-1 agents.

Practical Monitoring Schedule for Clinicians

The following schedule reflects the intersection of AWARD-PEDS safety monitoring, ADA pediatric diabetes standards, and the HealthRX developmental protocol for adolescents on GLP-1 therapy:

• Baseline: HbA1c, fasting glucose, BMI, height, weight, Tanner stage, lipid panel, LFTs, DXA (if age <16), PHQ-A, menstrual history (female patients)
• Month 1: Phone or telehealth check for GI tolerability; adjust intake patterns, not dose
• Month 3: HbA1c, BMI, height velocity review, PHQ-A; dose escalation decision
• Month 6: Full metabolic panel, Tanner staging, lipid panel, weight trajectory, menstrual history
• Month 12: Repeat DXA (if baseline performed), full metabolic panel, consideration of treatment continuation vs. Intensification

Special Populations Within the 12 to 17 Age Range

Early Adolescents (Ages 12 to 13)

This subgroup is in the most active phase of pubertal bone accrual and HPG axis maturation. The evidence base from AWARD-PEDS is thinner here because the trial enrolled from age 10, and the 12 to 13 subgroup was smaller than the 14 to 17 subgroup. Initiating dulaglutide in a 12-year-old with type 2 diabetes is clinically appropriate per FDA labeling, but closer developmental monitoring at 3-month intervals is warranted.

Adolescents With Obesity and Concurrent PCOS

Polycystic ovary syndrome (PCOS) affects approximately 6 to 18% of adolescent females and is closely linked to insulin resistance [17]. In adult PCOS populations, GLP-1 receptor agonists improve menstrual regularity and reduce androgen levels. Whether that benefit extends to adolescent PCOS is not established in a randomized trial. Off-label use for PCOS-related hyperandrogenism in a 12 to 17-year-old should not substitute for established PCOS management.

Adolescents on Concurrent Psychiatric Medications

Several atypical antipsychotics (olanzapine, quetiapine, clozapine) cause significant weight gain and insulin resistance. Dulaglutide may partially offset those metabolic effects. However, psychiatric medications that affect dopaminergic pathways interact with GLP-1 receptor agonist signaling in ways that are not yet characterized in adolescents. Consultation with the prescribing psychiatrist before initiating dulaglutide is required in this scenario.